Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F17%3A00475267" target="_blank" >RIV/61388963:_____/17:00475267 - isvavai.cz</a>

Výsledek na webu

<a href="https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-017-0144-0" target="_blank" >https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-017-0144-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12981-017-0144-0" target="_blank" >10.1186/s12981-017-0144-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals

Popis výsledku v původním jazyce

Progression rates from initial HIV-1 infection to advanced AIDS vary significantly among infected individuals. A distinct subgroup of HIV-1-infected individuals--termed viremic non-progressors (VNP) or controllers--do not seem to progress to AIDS, maintaining high CD4(+) T cell counts despite high levels of viremia for many years. Several studies have evaluated multiple host factors, including immune activation, trying to elucidate the atypical HIV-1 disease progression in these patients, however, limited work has been done to characterize viral factors in viremic controllers. We analyzed HIV-1 isolates from three VNP individuals and compared the replicative fitness, near full-length HIV-1 genomes and intra-patient HIV-1 genetic diversity with viruses from three typical (TP) and one rapid (RP) progressor individuals. Viremic non-progressors and typical patients were infected for > 10 years (range 10-17 years), with a mean CD4(+) T-cell count of 472 cells/mm(3) (442-529) and 400 cells/mm(3) (126-789), respectively. VNP individuals had a less marked decline in CD4(+) cells (mean -0.56, range -0.4 to -0.7 CD4(+)/month) than TP patients (mean -10.3, -8.2 to -13.1 CD4(+)/month). Interestingly, VNP individuals carried viruses with impaired replicative fitness, compared to HIV-1 isolates from the TP and RP patients (p < 0.05, 95% CI). Although analyses of the near full-length HIV-1 genomes showed no clear patterns of single-nucleotide polymorphisms (SNP) that could explain the decrease in replicative fitness, both the number of SNPs and HIV-1 population diversity correlated inversely with the replication capacity of the viruses (r = -0.956 and r = -0.878, p < 0.01, respectively). It is likely that complex multifactorial parameters govern HIV-1 disease progression in each individual, starting with the infecting virus (phenotype, load, and quasispecies diversity) and the intrinsic ability of the host to respond to the infection. Here we analyzed a subset of viremic controller patients and demonstrated that similar to the phenomenon observed in patients with a discordant response to antiretroviral therapy (i.e., high CD4(+) cell counts with detectable plasma HIV-1 RNA load), reduced viral replicative fitness seems to be linked to slow disease progression in these antiretroviral-naive individuals.

Název v anglickém jazyce

Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals

Popis výsledku anglicky

Progression rates from initial HIV-1 infection to advanced AIDS vary significantly among infected individuals. A distinct subgroup of HIV-1-infected individuals--termed viremic non-progressors (VNP) or controllers--do not seem to progress to AIDS, maintaining high CD4(+) T cell counts despite high levels of viremia for many years. Several studies have evaluated multiple host factors, including immune activation, trying to elucidate the atypical HIV-1 disease progression in these patients, however, limited work has been done to characterize viral factors in viremic controllers. We analyzed HIV-1 isolates from three VNP individuals and compared the replicative fitness, near full-length HIV-1 genomes and intra-patient HIV-1 genetic diversity with viruses from three typical (TP) and one rapid (RP) progressor individuals. Viremic non-progressors and typical patients were infected for > 10 years (range 10-17 years), with a mean CD4(+) T-cell count of 472 cells/mm(3) (442-529) and 400 cells/mm(3) (126-789), respectively. VNP individuals had a less marked decline in CD4(+) cells (mean -0.56, range -0.4 to -0.7 CD4(+)/month) than TP patients (mean -10.3, -8.2 to -13.1 CD4(+)/month). Interestingly, VNP individuals carried viruses with impaired replicative fitness, compared to HIV-1 isolates from the TP and RP patients (p < 0.05, 95% CI). Although analyses of the near full-length HIV-1 genomes showed no clear patterns of single-nucleotide polymorphisms (SNP) that could explain the decrease in replicative fitness, both the number of SNPs and HIV-1 population diversity correlated inversely with the replication capacity of the viruses (r = -0.956 and r = -0.878, p < 0.01, respectively). It is likely that complex multifactorial parameters govern HIV-1 disease progression in each individual, starting with the infecting virus (phenotype, load, and quasispecies diversity) and the intrinsic ability of the host to respond to the infection. Here we analyzed a subset of viremic controller patients and demonstrated that similar to the phenomenon observed in patients with a discordant response to antiretroviral therapy (i.e., high CD4(+) cell counts with detectable plasma HIV-1 RNA load), reduced viral replicative fitness seems to be linked to slow disease progression in these antiretroviral-naive individuals.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10607 - Virology

Projekt

<a href="/cs/project/LK11207" target="_blank" >LK11207: Role replikační zdatnosti HIV na průběh nemoci u pacientů bez antiretrovirové léčby</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

AIDS Research and Therapy

ISSN

1742-6405

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

Mar 20

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

17

Strana od-do

—

Kód UT WoS článku

000397757000001

EID výsledku v databázi Scopus

2-s2.0-85015618746